n.a. (OMTH)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Shares Outstanding 24.41M
Div & Yield N.A. (N.A)

Big Pharma Wants Fish Oil After All, But At Half Amarin's Selling Price

AstraZeneca buys Omthera Pharma to bolster its cardiovascular drug business.

Stock Futures Gain on Prospects for Improving Consumer Confidence

Stock futures point to a rebound Tuesday amid expectations of improved economic data and a spike in merger deals.

Millions for Fish Oil

Stocks are up as AstraZeneca pays millions for Omthera, while Valeant buys Bausch & Lomb and Tiffany's earnings shine.

Morning Briefing: 10 Things You Should Know

U.S. stock futures point higher; Valeant agrees to buy Bausch & Lomb; AstraZeneca to buy Omthera; 'Fast & Furious 6' takes in $120 million.

Stocks to Watch: Tiffany, United Natural Foods, Valeant

Tiffany is expected by analysts to report on Tuesday first-quarter earnings of 52 cents a share.

Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

5 Health Care Stocks Under $10 to Watch

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Omthera Pharmaceuticals, Inc. Announces Pricing Of Initial Public Offering

Company prices 8,000,000 shares of common stock at $8.00 per share

Biotech IPOs - Better To Wait These Out

Biotech IPOs, Omthera and Chimerix could have promising futures so IPO Desktop President tells TheStreet's Debra Borchardt that investors are probably better off waiting for that future.